RxDoctor Payments DataLook up a doctor →

Mardi Gomberg-Maitland, MD

Cardiovascular Disease · Washington, DCNPI 1548323066

Payments from drug & device makers

$1,062,192in general payments, 2019–2025

Across 286 payments — averaging $3713.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$847K
  • United Therapeutics Corporation$119K
  • Janssen Research & Development, LLC$50K
  • Sumitomo Pharma America, Inc.$15K
  • Bayer$12K
  • Actelion Pharmaceuticals US, Inc.$10K
  • plus $9K from 9 others
$20,154in research payments, 2019–2025

Across 12 payments — averaging $1679.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$20K

What the payments were for

  • Consulting fees$170,62253%
  • Speaking & faculty fees$47,06315%
  • Travel & lodging$95,21330%
  • Food & beverage$7,1372%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,062,192 in reported general payments places this provider in the 95th percentile of 105 cardiovascular disease providers in District of Columbia.

See all cardiovascular disease providers in District of Columbia

Medicare billing

Part B allowed, 2024
$47,167
Medicare patients
151
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag33$860,876
AdempasRiociguat36$608,950
LetairisAmbrisentan37$480,868
WinrevairSotatercept-Csrk17$318,322
Tyvaso DpiTreprostinil14$315,013
Ambrisentan63$240,881
EliquisApixaban37$47,949
Tadalafil49$33,849
JardianceEmpagliflozin22$26,145
Bumetanide36$3,490
Amiodarone Hcl25$1,329
Midodrine Hcl18$1,208
Digoxin31$775
Spironolactone22$706
Sildenafil Citrate14$365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi$9,951$860,87633 claims
BayerAdempas$12,393$608,95036 claims
MerckWinrevair$847,395$318,32217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 cardiovascular disease providers in District of Columbia.

Other cardiovascular disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →